NYSDA Publications

FDA Authorizes Use of Pfizer COVID-19 Vaccine Single Booster Dose for Persons Aged 5-11

The United States Food and Drug Administration (FDA) has authorized the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary vaccination series with the Pfizer novel coronavirus (COVID-19) vaccine.  FDA notes that while it has largely been the case that COVID-19 tends to be less severe in children than adults, the Omicron wave has seen more children getting sick with the disease and being hospitalized, and children may also experience longer term effects, even following initially mild disease.  To read the FDA announcement and summary of its authorizing a Pfizer COVID-19 vaccine booster dose for persons aged 5-11, use the link below.